302 related articles for article (PubMed ID: 24743332)
1. Increased microRNA-155 and decreased microRNA-146a may promote ocular inflammation and proliferation in Graves' ophthalmopathy.
Li K; Du Y; Jiang BL; He JF
Med Sci Monit; 2014 Apr; 20():639-43. PubMed ID: 24743332
[TBL] [Abstract][Full Text] [Related]
2. Role of miR-146a in the Regulation of Inflammation in an In Vitro Model of Graves' Orbitopathy.
Jang SY; Chae MK; Lee JH; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4027-34. PubMed ID: 27494344
[TBL] [Abstract][Full Text] [Related]
3. Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves' orbitopathy.
Jang SY; Park SJ; Chae MK; Lee JH; Lee EJ; Yoon JS
Br J Ophthalmol; 2018 Mar; 102(3):407-414. PubMed ID: 29101123
[TBL] [Abstract][Full Text] [Related]
4. Decreased microRNA-146a in CD4+T cells promote ocular inflammation in thyroid-associated ophthalmopathy by targeting NUMB.
Hu ZJ; He JF; Li KJ; Chen J; Xie XR
Eur Rev Med Pharmacol Sci; 2017 Apr; 21(8):1803-1809. PubMed ID: 28485799
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-146a downregulates the production of hyaluronic acid and collagen I in Graves' ophthalmopathy orbital fibroblasts.
Liu W; Ma C; Li HY; Chen L; Yuan SS; Li KJ
Exp Ther Med; 2020 Nov; 20(5):38. PubMed ID: 32952629
[TBL] [Abstract][Full Text] [Related]
6. Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy.
Wei H; Guan M; Qin Y; Xie C; Fu X; Gao F; Xue Y
Endocr J; 2014; 61(11):1087-92. PubMed ID: 25100151
[TBL] [Abstract][Full Text] [Related]
7. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
Dik WA; Virakul S; van Steensel L
Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of MicroRNA-146a/Notch2 Signaling Regulating IL-6 in Graves Ophthalmopathy.
Wang N; Chen FE; Long ZW
Cell Physiol Biochem; 2017; 41(4):1285-1297. PubMed ID: 28278511
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
Wall JR; Lahooti H
Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
[TBL] [Abstract][Full Text] [Related]
10. Integrative Analysis of Proteomics and DNA Methylation in Orbital Fibroblasts From Graves' Ophthalmopathy.
Virakul S; Somparn P; Pisitkun T; van der Spek PJ; Dalm VASH; Paridaens D; van Hagen PM; Hirankarn N; Palaga T; Dik WA
Front Endocrinol (Lausanne); 2020; 11():619989. PubMed ID: 33658982
[TBL] [Abstract][Full Text] [Related]
11. TSHR Signaling Stimulates Proliferation Through PI3K/Akt and Induction of miR-146a and miR-155 in Thyroid Eye Disease Orbital Fibroblasts.
Woeller CF; Roztocil E; Hammond C; Feldon SE
Invest Ophthalmol Vis Sci; 2019 Oct; 60(13):4336-4345. PubMed ID: 31622470
[TBL] [Abstract][Full Text] [Related]
12. Molecular biomarkers of Graves' ophthalmopathy.
Longo CM; Higgins PJ
Exp Mol Pathol; 2019 Feb; 106():1-6. PubMed ID: 30414981
[TBL] [Abstract][Full Text] [Related]
13. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy.
Feldon SE; Park DJ; O'Loughlin CW; Nguyen VT; Landskroner-Eiger S; Chang D; Thatcher TH; Phipps RP
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):3913-21. PubMed ID: 16249464
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-183 and microRNA-96 are associated with autoimmune responses by regulating T cell activation.
Thiel J; Alter C; Luppus S; Eckstein A; Tan S; Führer D; Pastille E; Westendorf AM; Buer J; Hansen W
J Autoimmun; 2019 Jan; 96():94-103. PubMed ID: 30201436
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of oculometric variables in Graves' ophthalmopathy.
Miot HA; Fernandes LP; Jorge EN; Pivotto DR; Nogueira CR; Mazeto GM
Clinics (Sao Paulo); 2009; 64(9):885-9. PubMed ID: 19759882
[TBL] [Abstract][Full Text] [Related]
16. MiRNA-21 promotes fibrosis in orbital fibroblasts from thyroid-associated ophthalmopathy.
Tong BD; Xiao MY; Zeng JX; Xiong W
Mol Vis; 2015; 21():324-34. PubMed ID: 25873777
[TBL] [Abstract][Full Text] [Related]
17. Emerging Insights Into the Role of Epigenetics and Gut Microbiome in the Pathogenesis of Graves' Ophthalmopathy.
Wang Y; Ma XM; Wang X; Sun X; Wang LJ; Li XQ; Liu XY; Yu HS
Front Endocrinol (Lausanne); 2021; 12():788535. PubMed ID: 35069441
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood T lymphocyte sensitisation against calsequestrin and flavoprotein in patients with Graves' ophthalmopathy.
Nguyen B; Gopinath B; Tani J; Wescombe L; Wall JR
Autoimmunity; 2008 Aug; 41(5):372-6. PubMed ID: 18568642
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-155 acts as an anti-inflammatory factor in orbital fibroblasts from Graves' orbitopathy by repressing interleukin-2-inducible T-cell kinase.
Choi YJ; Kim C; Choi EW; Lee SH; Chae MK; Jun HO; Kim BY; Yoon JS; Jang SY
PLoS One; 2022; 17(8):e0270416. PubMed ID: 35980936
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms That Underly T Cell Immunity in Graves' Orbitopathy.
Fang S; Lu Y; Huang Y; Zhou H; Fan X
Front Endocrinol (Lausanne); 2021; 12():648732. PubMed ID: 33868176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
